Bendamustine Sandoz (Bendamustine)
bendamustine hydrochloride 100 mg injection, 1 vial · INJECTION · PBS code 10763L
STREAMLINEDWhat it costs
AU$58.49 PBS-determined price per pack
Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.
- • First listed on the PBS: 2023-08-01.
- • Repeats: 11.
- • PBS program: IN.
Eligibility criteria for subsidised access
The following is the government's own wording from the PBS Schedule, shown unchanged.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Previously untreated stage III or IV mantle cell lymphoma
Induction treatment
The condition must be CD20 positive; AND
The treatment must be in combination with rituximab; AND
The condition must be previously untreated; AND
The condition must be symptomatic; AND
The treatment must be for induction treatment purposes only; AND
Patient must not receive more than 6 cycles (12 doses) of treatment under this restriction; AND
Patient must not be eligible for stem cell transplantation.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Previously untreated stage II bulky or stage III or IV indolent non-Hodgkin's lymphoma
Induction treatment
The condition must be CD20 positive; AND
The condition must be previously untreated; AND
The condition must be symptomatic; AND
The treatment must be for induction treatment purposes only; AND
The treatment must be in combination with rituximab or obinutuzumab; AND
The treatment must not exceed 6 cycles (12 doses) with this drug under this restriction.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Follicular lymphoma
Re-induction treatment
The condition must be CD20 positive; AND
The condition must be refractory to treatment with rituximab for this condition; AND
The condition must be symptomatic; AND
The treatment must be for re-induction treatment purposes only; AND
The treatment must be in combination with obinutuzumab; AND
The treatment must not exceed 6 cycles (12 doses) with this drug under this restriction.
The condition is considered rituximab-refractory if the patient experiences less than a partial response or progression of disease within 6 months after completion of a prior rituximab-containing regimen.
Sponsor: Sandoz Pty Ltd ABN 60 075 449 553
Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.